文献速递艾滋病与性传播感染

严重免疫抑制与HIV感染者对SARS-CoV-2疫苗免疫原性较差相关

Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV.
PubMed 文献 · Clin Microbiol Infect · 2022-05-28

该多中心前瞻性队列研究纳入420例已完成标准免疫接种(mRNA或腺病毒载体COVID-19疫苗)的HIV感染者,评估疫苗接种后1至2个月内的抗体应答。结果显示,CD4计数<200 cells/mm3者血清转化率明显低于CD4计数较高者,多因素分析中CD4计数≥350 cells/mm3和接种mRNA载体COVID-19疫苗与更高的应答概率独立相关。作者认为HIV相关免疫抑制损害对SARS-CoV-2疫苗的抗体应答,应尽快为此类人群制定特异性接种方案,并尽可能避免使用腺病毒载体疫苗。

要点

  • 420例HIV感染者中384例(91%)接种后出现抗体应答。
  • CD4<200 cells/mm3者血清转化率为64%,明显低于CD4≥350 cells/mm3者的95%。
  • CD4≥350 cells/mm3(OR 7.10)与接种mRNA载体疫苗(OR 8.19)独立关联更高应答概率。

核心结论

  • HIV相关免疫抑制损害对SARS-CoV-2疫苗的抗体应答。
  • 作者认为应尽快为HIV感染者制定特异性接种方案,尤其是CD4细胞计数<200 cells/μL者。
  • 作者认为HIV感染者应尽可能避免使用腺病毒载体疫苗。

研究设计与样本

  • 多中心前瞻性队列研究,纳入420例已完成标准免疫接种(mRNA或腺病毒载体COVID-19疫苗)的HIV感染者。
  • 于最后一剂疫苗接种后1至2个月内定量检测抗三聚体刺突蛋白特异性IgG抗体和IgG中和抗体以评估抗体应答。

主要发现

  • 420例HIV感染者中384例(91%)出现抗体应答。
  • CD4计数≥350 cells/mm3者308/326例(95%)、200至349 cells/mm3者55/61例(90%)、<200 cells/mm3者21/33例(64%)出现血清转化(p < 0.001)。
  • IgG中和抗体水平中位log10值:CD4<200 cells/mm3者为2.4 IU/mL(Q1-Q3,1.0-3.1),200至349 cells/mm3组为3.1 IU/mL(Q1-Q3,2.8-3.4),CD4≥350 cells/mm3者为3.1 IU/mL(Q1-Q3,2.7-3.4)(p = 0.016)。
  • 多因素分析中,CD4计数≥350 cells/mm3(OR:7.10;95% CI,1.91-26.46;p = 0.004)与接种mRNA载体COVID-19疫苗(OR:8.19;95% CI,3.24-20.70;p ≤ 0.001)与更高的疫苗应答概率独立相关。

临床怎么用

  • 作者认为应尽快为HIV感染者制定特异性接种方案,尤其是CD4细胞计数<200 cells/μL者。
  • 作者认为HIV感染者应尽可能避免使用腺病毒载体疫苗。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The aim of this study was to assess the immunogenicity of SARS-CoV-2 available vaccines among people living with HIV (PLWH) after a complete vaccination scheme, and determine predictors of seroconversion. METHODS: This multicentre prospective cohort study included 420 PLWH who had received a standard immunization, either with mRNA or adenoviral-vectored COVID-19 vaccines. Antibody response was evaluated within 1 to 2 months after the last dose of the vaccine with a quantitative determination of antitrimeric spike protein-specific IgG antibodies and IgG neutralizing antibodies. RESULTS: Overall, 384 of 420 PLWH (91%) showed antibody response to vaccination. Seroconversion was observed in 308 of 326 individuals with cluster of differentiation 4 (CD4) counts ≥350 cells/mm3 (95%), 55 of 61 PLWH with 200 to 349 cells/mm3 (90%), and 21 of 33 PLWH with CD4 counts <200 cells/mm3 (64%; p < 0.001). The median log10 IgG neutralization levels were 2.4 IU/mL (Q1-Q3, 1.0-3.1) among PLWH with CD4 counts <200 cells/mm3, 3.1 IU/mL (Q1-Q3, 2.8-3.4) for the 200 to 349 cells/mm3 group, and 3.1 IU/mL (Q1-Q3, 2.7-3.4) for PLWH with CD4 counts ≥350 cells/mm3 (p = 0.016). In the multivariate analysis, CD4 counts ≥350 cells/mm3 (OR: 7.10; 95% CI, 1.91-26.46; p = 0.004) and receiving mRNA-vectored COVID-19 vaccines (OR: 8.19; 95% CI, 3.24-20.70; p ≤ 0.001) were independently associated with a higher probability of response to vaccination. DISCUSSION: HIV-related immunosuppression impairs the antibody response to SARS-CoV-2 vaccines. Specific vaccination schemes should be urgently tailored in this setting, particularly in patients with CD4 cell counts <200 cells/μL. Adenoviral-vectored vaccines should be avoided in PLWH whenever possible.

来源:Clin Microbiol Infect,查看原文。版权归原作者所有。

引用

  1. Corma-Gómez A, Fernández-Fuertes M, García E, et al. Severe immunosuppression is related to poorer immunogenicity to SARS-CoV-2 vaccines among people living with HIV. Clin Microbiol Infect. 2022. PMID: 35640840. doi:10.1016/j.cmi.2022.05.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。